Electrocore, Inc. (ECOR) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Electrocore, Inc. (ECOR) stock forecast summary
Our AI ranks Electrocore, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Electrocore, Inc. is a small-cap company with a market capitalization of $71M. It ranks number 18 by market capitalization among the 30 Electromedical & Electrotherapeutic Apparatus issuers in our coverage with a current forecast.
For ECOR, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 12.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 4.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ECOR included.
Follow ECOR freeECOR price chart and AI forecast
How ECOR ranks among 5171 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Electrocore, Inc. (ECOR) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Electromedical & Electrotherapeutic Apparatus peers listed below that report each metric.
Valuation & Market
| Metric | ECOR | Rank |
|---|---|---|
| Market Cap | $71M | 18/30 |
| EPS | $-1.54 | – |
| Revenue/Share | $4.10 | – |
| FCF/Share | $-1.08 | – |
Profitability & Margins
| Metric | ECOR | Rank |
|---|---|---|
| ROA | -86.6% | 21/24 |
| Gross Margin | 87.1% | 2/27 |
| Operating Margin | -37.6% | 17/28 |
| Net Margin | -40.0% | 14/22 |
| EBT Margin | -40.7% | 16/28 |
| Tax Rate | 1.8% | – |
Financial Health
| Metric | ECOR | Rank |
|---|---|---|
| Current Ratio | 1.21x | 25/30 |
| Quick Ratio | 1.00x | 22/29 |
| Interest Coverage | -840.0x | 29/30 |
| Working Capital | $2M | 23/29 |
Cash Flow
| Metric | ECOR | Rank |
|---|---|---|
| Operating Cash Flow | -$10M | 22/30 |
| Free Cash Flow | -$10M | 7/14 |
| Capital Spending | -$10K | 1/14 |
| FCF/Sales | -26.4% | 7/14 |
| CapEx/Sales | 0.0% | 14/14 |
Operational Efficiency
| Metric | ECOR | Rank |
|---|---|---|
| Asset Turnover | 2.17x | 1/19 |
| Receivables Turnover | 40.7x | 2/20 |
| Inventory Turnover | 2.0x | 14/27 |
| Fixed Assets Turnover | 98.6x | 2/20 |
| Days Sales Outstanding | 9 days | 19/20 |
| Days Inventory | 184 days | 14/27 |
| Payables Period | 166 days | 7/24 |
| Cash Conversion Cycle | 27 days | 14/19 |
Income Statement
| Metric | ECOR | Rank |
|---|---|---|
| Total Revenue | $37M | 12/19 |
| Operating Income | -$14M | 23/30 |
| Net Income | -$15M | 18/24 |
| R&D Expense | $3M | 18/28 |
| SG&A Expense | $43M | 13/26 |
| Cost of Goods Sold | $5M | 20/27 |
Dividend & Shareholder Information
| Metric | ECOR | Rank |
|---|---|---|
| Shares Outstanding | 9M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $14M | |
| Cash & Short-term Investments | $8M | |
| Accounts Receivable | $910K | |
| Inventory | $2M | |
| Total Liabilities | $20M | |
| Short-term Debt | $9M |
ECOR quarterly financials and insider trading
Electrocore, Inc. (ECOR) industry peers
Companies classified under the same SEC industry code as Electrocore, Inc. (Electromedical & Electrotherapeutic Apparatus): 32 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| ECOR Electrocore, Inc. | ▲ | $71M |
| MDT Medtronic Plc | ▼ | $121.20B |
| ITGR Integer Holdings Corp | ▼ | $4.31B |
| LIVN Livanova Plc | ▼ | $4.27B |
| TMDX Transmedics Group, Inc. | ▲ | $2.65B |
| BLFS Biolife Solutions Inc | ▶ | $1.89B |
| AXGN Axogen, Inc. | ▲ | $1.86B |
| CNMD Conmed Corp | ▼ | $1.40B |
| CBLL Ceribell, Inc. | ▲ | $961M |
| INMD Inmode Ltd. | ▼ | $814M |
| CV Capsovision, Inc | ▶ | $323M |
| ELMD Electromed, Inc. | ▼ | $229M |
| FOCL Edap Tms Sa | ▲ | $153M |
| VANI Vivani Medical, Inc. | ▶ | $104M |
| STXS Stereotaxis, Inc. | ▶ | $101M |
| NRXS Neuraxis, Inc | ▲ | $97M |
| HYPR Hyperfine, Inc. | ▲ | $77M |
| OM Outset Medical, Inc. | ▲ | $77M |
| POSC Positron Corp | ▲ | $53M |
| VASO Vaso Corp | ▲ | $51M |
| POCI Precision Optics Corporation, Inc. | ▲ | $48M |
| QTI Qt Imaging Holdings, Inc. | ▶ | $35M |
| ITOC Itonic Holdings Ltd | ▼ | $29M |
| GTHP Guided Therapeutics Inc | ▲ | $18M |
| IRIX Iridex Corp | ▲ | $14M |
| NDRA Endra Life Sciences Inc. | ▶ | $7M |
| ADMT Adm Tronics Unlimited, Inc. | ▶ | $3M |
| NXL Nexalin Technology, Inc. | ▼ | $2M |
| NUWE Nuwellis, Inc. | ▼ | $2M |
| ESMC Escalon Medical Corp | ▲ | $1M |
| HCIL Hongchang International Co., Ltd | ▼ | N/A |
| YBGJ Yubo International Biotech Ltd | ▶ | N/A |
Where ECOR sits on the market map
Electrocore, Inc. (ECOR) stock news
Loading...
Electrocore, Inc. (ECOR) stock forecast FAQ
What is the Electrocore, Inc. (ECOR) stock forecast?
Our AI ranks Electrocore, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Electrocore, Inc. stock predictions?
For ECOR, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 12.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 4.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Electrocore, Inc. forecasts updated?
Electrocore, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Electrocore, Inc.'s industry peers?
32 issuers in our coverage, ECOR included, share the SEC industry code Electromedical & Electrotherapeutic Apparatus. The largest are: Medtronic Plc (MDT), Integer Holdings Corp (ITGR), Livanova Plc (LIVN), Transmedics Group, Inc. (TMDX), Biolife Solutions Inc (BLFS), Axogen, Inc. (AXGN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.